This portal is your one-stop-shop for all your needs and questions concerning BMS products in Switzerland! These are some examples of the things you can find:
September 2023 – Swissmedic approved Lisocabtagene maraleucel (BREYANZI®) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
July 2023 – Nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumor size ≥ 4cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumor expression ≥1% in adults
July 2022 – Nivolumab in combination with Ipilimumab or with fluoropyrimidine- and cisplatinum-based chemotherapy for the first-line treatment of patients with advanced or metastatic oesophageal squamous cell carcinoma (PD-L1 ≥ 1%) not amenable to curative treatment
March 2022 – Swissmedic approved Lisocabtagene maraleucel (liso-cel, BREYANZI®) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), or primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy.
Ready to explore? Please use your existing DocCheck Login to access one of our therapeutic area portals, or access the comprehensive BMS medicines or news & events overview